BR112014012681A2 - polipeptídeo, métido para proporcionar um polipeptídeo, ácido nucleico, e, composição imunogênica - Google Patents

polipeptídeo, métido para proporcionar um polipeptídeo, ácido nucleico, e, composição imunogênica

Info

Publication number
BR112014012681A2
BR112014012681A2 BR112014012681A BR112014012681A BR112014012681A2 BR 112014012681 A2 BR112014012681 A2 BR 112014012681A2 BR 112014012681 A BR112014012681 A BR 112014012681A BR 112014012681 A BR112014012681 A BR 112014012681A BR 112014012681 A2 BR112014012681 A2 BR 112014012681A2
Authority
BR
Brazil
Prior art keywords
polypeptide
designed
nucleic acid
immunogenic composition
immunogenic
Prior art date
Application number
BR112014012681A
Other languages
English (en)
Other versions
BR112014012681A8 (pt
Inventor
Impagliazzo Antonietta
Wilem Meijberg Jan
Radosevic Katarina
Alard Philippe
Heinz Edward Friesen Robert
Vogels Ronald
Loverix Stefan
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of BR112014012681A2 publication Critical patent/BR112014012681A2/pt
Publication of BR112014012681A8 publication Critical patent/BR112014012681A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014012681A 2011-11-28 2012-11-27 polipeptídeo, métido para proporcionar um polipeptídeo, ácido nucleico, e, composição imunogênica BR112014012681A8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161564198P 2011-11-28 2011-11-28
US201161564086P 2011-11-28 2011-11-28
EP11191003 2011-11-28
EP11191009 2011-11-28
EP12166268 2012-05-01
US201261720281P 2012-10-30 2012-10-30
PCT/EP2012/073706 WO2013079473A1 (en) 2011-11-28 2012-11-27 Influenza virus vaccines and uses thereof

Publications (2)

Publication Number Publication Date
BR112014012681A2 true BR112014012681A2 (pt) 2017-06-13
BR112014012681A8 BR112014012681A8 (pt) 2017-06-20

Family

ID=48534691

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014012681A BR112014012681A8 (pt) 2011-11-28 2012-11-27 polipeptídeo, métido para proporcionar um polipeptídeo, ácido nucleico, e, composição imunogênica

Country Status (20)

Country Link
US (3) US9452211B2 (pt)
EP (2) EP2785372B1 (pt)
JP (1) JP6294828B2 (pt)
KR (1) KR101983989B1 (pt)
CN (1) CN104066446B (pt)
AR (1) AR089005A1 (pt)
AU (1) AU2012343981B2 (pt)
BR (1) BR112014012681A8 (pt)
CA (1) CA2857087C (pt)
EA (1) EA033386B1 (pt)
HK (1) HK1199211A1 (pt)
IL (1) IL232780A (pt)
IN (1) IN2014CN04742A (pt)
MX (1) MX357009B (pt)
MY (1) MY170927A (pt)
PH (1) PH12014501118B1 (pt)
SG (1) SG11201402633UA (pt)
TW (1) TWI618715B (pt)
WO (1) WO2013079473A1 (pt)
ZA (1) ZA201404797B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3009145A1 (en) 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
AU2011217903B2 (en) 2010-02-18 2017-03-02 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
EP3248615A1 (en) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
IN2014CN02114A (pt) 2011-09-20 2015-05-29 Sinai School Medicine
EP2785372B1 (en) 2011-11-28 2019-06-19 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
WO2013177444A2 (en) * 2012-05-23 2013-11-28 The Board Of Trustees Of The Leland Stanford Junior University Influenza vaccine constructs
EP4154907A1 (en) 2012-12-18 2023-03-29 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP3004142B1 (en) * 2013-05-30 2020-09-30 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
JP6704849B2 (ja) * 2013-08-03 2020-06-03 アバター・メディカル・エルエルシー インフルエンザヘマグルチニンタンパク質およびその方法
EP3137487B1 (en) * 2014-05-01 2021-03-03 Indian Institute of Science Polypeptides for generating anti-influenza antibodies and uses thereof
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
BR112016030183A2 (pt) 2014-06-26 2017-11-14 Janssen Vaccines & Prevention Bv anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
CA2952351C (en) 2014-07-10 2023-10-17 Antonietta IMPAGLIAZZO Influenza virus vaccines and uses thereof
IL249704B (en) * 2014-07-10 2021-03-25 Janssen Vaccines & Prevention Bv Influenza virus vaccines and their uses
SG11201610456UA (en) * 2014-07-10 2017-01-27 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
WO2016118937A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
WO2016180826A1 (en) * 2015-05-11 2016-11-17 Janssen Vaccines & Prevention B.V. Influenza virus neutralizing peptidomimetic compounds
US10538557B2 (en) 2015-09-02 2020-01-21 Janssen Vaccines & Prevention B.V. Stabilized viral class I fusion proteins
CN109641041A (zh) 2016-06-15 2019-04-16 西奈山伊坎医学院 流感病毒血细胞凝集素蛋白及其用途
SG10201912944QA (en) * 2016-09-02 2020-02-27 The Usa As Represented By The Secretary Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
CN110325208A (zh) * 2016-09-16 2019-10-11 威克斯技术公司 针对流感的疫苗接种的组合物和方法
EP3939604A3 (en) * 2016-10-21 2022-06-22 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
WO2019100147A1 (en) * 2017-11-22 2019-05-31 Her Majesty the Queen in the Right of Canada as represented by the Minister of Health Synthetic hemagglutinin as universal vaccine against infection by type b influenza viruses (ibv)
CN111556896A (zh) 2017-12-21 2020-08-18 株式会社绿色生物医药 交叉免疫抗原疫苗及其制备方法
HRP20220980T1 (hr) 2018-01-23 2022-11-11 Janssen Vaccines & Prevention B.V. Cjepiva protiv virusa influence i njihova uporaba
AU2020263900A1 (en) * 2019-04-25 2021-10-14 Janssen Vaccines & Prevention B.V. Recombinant influenza antigens
WO2021043869A1 (en) 2019-09-05 2021-03-11 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
AU2020367242A1 (en) * 2019-10-15 2022-04-14 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
WO2022051327A1 (en) * 2020-09-02 2022-03-10 St. Jude Children's Research Hospital, Inc. Hemagglutinin modifications for improved influenza vaccine production
EP4210740A1 (en) 2020-09-07 2023-07-19 Intervet International B.V. Ha stem vaccine for ha antibody-positive targets
CA3222568A1 (en) * 2021-06-28 2023-01-05 Glaxosmithkline Biologicals Sa Novel influenza antigens
WO2024038382A1 (en) * 2022-08-16 2024-02-22 Seqirus Inc. Modified influenza viruses
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
CN116947982B (zh) * 2023-07-12 2024-05-14 吉林大学 三条优势表位肽序列及其在流感病毒疫苗的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
JP3037554B2 (ja) * 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6248780B1 (en) 1998-10-01 2001-06-19 Duquesne University Of The Holy Ghost Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE60116513T2 (de) 2000-08-10 2006-09-21 Crucell Holland B.V. Adenovirenvektoren zur transduktion der chondrozyten
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
PL208588B1 (pl) 2002-04-25 2011-05-31 Crucell Holland Bv Rekombinowane adenowirusy, wyizolowane kwasy nukleinowe, komórki pakujące oraz sposoby zwiększania stabilności i/lub pojemności upakowania rekombinowanego adenowirusa
DK1497438T3 (da) 2002-04-25 2010-01-04 Crucell Holland Bv Midler og fremgangsmåder til fremstilling af adenovirusvektorer
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20050221493A1 (en) 2002-12-04 2005-10-06 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
WO2005033320A1 (en) 2003-10-02 2005-04-14 Crucell Holland B.V. Packaging cells for recombinant adenovirus
AU2005305869B2 (en) 2004-11-16 2010-12-09 Aeras Global Tb Vaccine Foundation Multivalent vaccines comprising recombinant viral vectors
KR101485197B1 (ko) * 2006-09-07 2015-01-23 크루셀 홀란드 비.브이. 인플루엔자 바이러스 ｈ5ｎ1을 중화시킬 수 있는 인간 결합분자 및 그것의 용도
EP3009145A1 (en) * 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
SG176003A1 (en) * 2009-05-11 2011-12-29 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
EP3248615A1 (en) * 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
ES2608321T3 (es) 2011-07-14 2017-04-07 Janssen Vaccines & Prevention B.V. Moléculas de unión humanas capaces de neutralizar virus de la gripe A del grupo filogenético 1 y del grupo filogenético 2 y virus de la gripe B
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
EP2785372B1 (en) 2011-11-28 2019-06-19 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US20130236494A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Vaccination against influenza
US8834881B2 (en) 2012-03-08 2014-09-16 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
CA2884388A1 (en) 2012-09-27 2014-04-03 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing hepatitis b viruses and uses thereof
EP3004142B1 (en) 2013-05-30 2020-09-30 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
CA2952351C (en) 2014-07-10 2023-10-17 Antonietta IMPAGLIAZZO Influenza virus vaccines and uses thereof
SG11201610456UA (en) 2014-07-10 2017-01-27 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof

Also Published As

Publication number Publication date
JP6294828B2 (ja) 2018-03-14
CA2857087C (en) 2021-05-25
TWI618715B (zh) 2018-03-21
EP3566714A1 (en) 2019-11-13
ZA201404797B (en) 2022-03-30
CN104066446A (zh) 2014-09-24
PH12014501118A1 (en) 2014-08-04
KR101983989B1 (ko) 2019-05-31
TW201329101A (zh) 2013-07-16
HK1199211A1 (en) 2015-06-26
BR112014012681A8 (pt) 2017-06-20
CA2857087A1 (en) 2013-06-06
NZ625973A (en) 2016-09-30
US20160362455A1 (en) 2016-12-15
JP2015502353A (ja) 2015-01-22
IL232780A0 (en) 2014-07-31
CN104066446B (zh) 2017-10-03
KR20140099515A (ko) 2014-08-12
EA201491051A1 (ru) 2015-04-30
MX2014006396A (es) 2014-07-22
AU2012343981B2 (en) 2017-09-07
MY170927A (en) 2019-09-19
US9969778B2 (en) 2018-05-15
US20140357845A1 (en) 2014-12-04
MX357009B (es) 2018-06-22
EP2785372B1 (en) 2019-06-19
IN2014CN04742A (pt) 2015-09-18
US20160355553A1 (en) 2016-12-08
WO2013079473A1 (en) 2013-06-06
EA033386B1 (ru) 2019-10-31
AU2012343981A1 (en) 2014-07-10
IL232780A (en) 2017-09-28
SG11201402633UA (en) 2014-09-26
EP2785372A1 (en) 2014-10-08
PH12014501118B1 (en) 2014-08-04
US9452211B2 (en) 2016-09-27
AR089005A1 (es) 2014-07-23

Similar Documents

Publication Publication Date Title
BR112014012681A8 (pt) polipeptídeo, métido para proporcionar um polipeptídeo, ácido nucleico, e, composição imunogênica
SMT201700110B (it) Composizione immunogena
BR112014000787A2 (pt) método para produzir vírus vaccinia
DK2387989T3 (da) Langtidsvirkende formuleringer med insuliner
DK2694038T3 (da) Farmaceutisk sammensætning
DK3623481T3 (da) Sammensætninger til nukleinsyresekventering
BR112013013405A2 (pt) embalagem, matriz para formar um carregador, e método para formar uma embalagem
BR112015010947A2 (pt) composições e métodos para aumentar o metabolismo energético.
BR112014010290A2 (pt) composição farmacêutica, métodos, composições e usos
DK3050972T3 (da) Fremgangsmåder til fremstilling af eicosapentaensyre i thraustochytrider
BR112014003566A2 (pt) célula hospedeira recombinante, e, método para produzir um ácido c4-dicarboxílico
BR112014013682A2 (pt) composição para cuidado pessoal
BR112014003444A2 (pt) célula hospedeira recombinante, e, método para produzir um ácido c4-dicarboxílico
BR112013014103A2 (pt) método para produzir um l-aminoácido
BR112013022556A2 (pt) composição farmacêutica aquosa semissólida contendo tapentadol
BR112013023465A2 (pt) método para produzir l-cisteína
BR112013014777A2 (pt) método para formar um eletrodo bipolar
DK2736888T3 (da) 3-heteroaroylaminopropionsyrederivater og deres anvendelse som farmaceutika
BR112013031360A2 (pt) método para produzir um composto, e, composto
BR112013022306A2 (pt) método, e, composição
BR112014005614A2 (pt) método para produzir chocolate, e, chocolate
BR112013033851A2 (pt) método para formar sevoflurano
BR112014003151A2 (pt) métodos para produzir biodiesel
BR112013019224A2 (pt) composição, e metodo
FR2978964B1 (fr) Composition vaccinale anti-il-6

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: JANSSEN VACCINES AND PREVENTION B.V (NL)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: JANSSEN VACCINES AND PREVENTION B.V. (NL)

B25G Requested change of headquarter approved

Owner name: JANSSEN VACCINES AND PREVENTION B.V. (NL)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time